A Phase 2 Study to Investigate in Itanapraced in Parkinson's Disease Patients With and Without Genetic Mutation
Latest Information Update: 01 Apr 2019
At a glance
- Drugs Itanapraced (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
Most Recent Events
- 26 Mar 2019 According to a CereSpir media release, the company announced the formation of an expanded Clinical Advisory Board (CAB) chaired by Professor Robert A. Hauser to support Phase 2 clinical development of its lead compound itanapraced in Parkinson's disease (PD).
- 26 Mar 2019 According to a CereSpir media release, this phase 2 trial is expected to initiate this year.
- 24 Dec 2018 New trial record